INT38788

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1985
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 4.50
Pain Relevance 1.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (CYSLTR1) signal transducer activity (CYSLTR1)
Anatomy Link Frequency
heart 1
hippocampus 1
CYSLTR1 (Homo sapiens)
Pain Link Frequency Relevance Heat
long-term potentiation 14 100.00 Very High Very High Very High
Hippocampus 10 99.68 Very High Very High Very High
Spinal cord 2 96.48 Very High Very High Very High
Inflammation 18 90.64 High High
aspirin 80 89.48 High High
lidocaine 2 89.44 High High
agonist 46 87.24 High High
antagonist 25 85.36 High High
cINOD 3 70.36 Quite High
cytokine 5 68.12 Quite High
Disease Link Frequency Relevance Heat
Asthma 175 98.48 Very High Very High Very High
Frailty 2 96.76 Very High Very High Very High
Autism 314 94.76 High High
Cv Unclassified Under Development 2 94.44 High High
Retts Disease 6 93.96 High High
Intellectual Impairment 24 90.92 High High
INFLAMMATION 22 90.64 High High
Occupational Lung Diseases 19 86.68 High High
Targeted Disruption 3 85.44 High High
Rhinitis 8 84.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Antileukotriene therapies inhibit leukotriene synthesis by inhibiting 5-lipoxygenase (5-LO) or by blocking the cysteinyl leukotriene receptor.
Negative_regulation (blocking) of cysteinyl leukotriene receptor
1) Confidence 0.42 Published 2010 Journal Allergy, Asthma & Immunology Research Section Body Doc Link PMC2892049 Disease Relevance 0.45 Pain Relevance 0.20
Blood flow was kept constant during elevation by 20 cm above heart level (preserved autoregulation) except after injection of PGE-2 and LTD-4 20 microM where a significant decrease was observed (defective smooth muscle function).
Negative_regulation (decrease) of LTD-4 in heart
2) Confidence 0.36 Published 1985 Journal Prostaglandins Section Abstract Doc Link 3856899 Disease Relevance 0.08 Pain Relevance 0.18
Very recently, GPR17 was shown to function as a negative regulator of CysLT1 receptor activation in stable cell lines by inhibiting LTD4 binding to CysLT1.
Negative_regulation (regulator) of CysLT1
3) Confidence 0.28 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2839267 Disease Relevance 0.45 Pain Relevance 0.08
The LT synthesis inhibitor blocks key steps in the biosynthetic pathway (either 5-LO or 5-LO activating protein—FLAP) to inhibit production of both Cys-LTs and LTB4, whereas the LTRAs selectively block the CysLT1 receptor on target cells.
Negative_regulation (block) of CysLT1 receptor
4) Confidence 0.27 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2817543 Disease Relevance 0.56 Pain Relevance 0.04
In contrast, an intravenous infusion of FPL 55712 failed to block the bronchospastic activity of LTD4.
Negative_regulation (block) of LTD4
5) Confidence 0.19 Published 1986 Journal Prostaglandins Section Abstract Doc Link 3823489 Disease Relevance 0 Pain Relevance 0.04
CysLTs exert their biological actions by binding to two types of G protein-coupled receptors, i.e., cysteinyl leukotriene receptor 1 (CYSLTR1), which is sensitive to the asthma drugs montelukast (MLK), zafirlukast, and pranlukast,8,9 and CYSLTR2.10
Negative_regulation (types) of cysteinyl leukotriene receptor 1 associated with asthma
6) Confidence 0.11 Published 2010 Journal Allergy, Asthma & Immunology Research Section Body Doc Link PMC2831603 Disease Relevance 1.22 Pain Relevance 0.42
Antileukotriene therapies inhibit synthesis of leukotrienes through ALOX5 inhibition or by blocking the cysteinyl leukotriene receptor.
Negative_regulation (blocking) of leukotriene receptor
7) Confidence 0.09 Published 2010 Journal Indian Journal of Human Genetics Section Body Doc Link PMC3009420 Disease Relevance 0.43 Pain Relevance 0.05
MeCP2 ko mice exhibited impaired LTP and LTD in the hippocampus (Asaka et al., 2006; Moretti et al., 2006) and additionally also impaired LTP in the primary motor and sensory cortices (Moretti et al., 2006), which is commonly interpreted as being in line with the severe mental retardation observed in RTT and extrapolated to autism as well.
Negative_regulation (impaired) of LTD in hippocampus associated with autism, intellectual impairment, retts disease, hippocampus and long-term potentiation
8) Confidence 0.00 Published 2010 Journal Frontiers in Human Neuroscience Section Body Doc Link PMC3010743 Disease Relevance 1.31 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox